These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies. Del Vecchio L; Locatelli F Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373 [TBL] [Abstract][Full Text] [Related]
24. Chronic kidney disease anemia management: what should be done? Szczech LA Blood Purif; 2011; 31(1-3):186-8. PubMed ID: 21228588 [TBL] [Abstract][Full Text] [Related]
25. CE: Continuing Education Article: MANAGEMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE. Chamney M; Pugh-Clarke K; Kafkia T; Wittwer I J Ren Care; 2010 Jun; 36(2):102-11. PubMed ID: 20591006 [TBL] [Abstract][Full Text] [Related]
26. Managing anaemia of chronic kidney disease. Murphy F; Bennett L; Jenkins K Br J Nurs; 2010 Nov 11-24; 19(20):1281-2, 1284-6. PubMed ID: 21072014 [TBL] [Abstract][Full Text] [Related]
27. Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy? Locatelli F; Del Vecchio L Expert Opin Pharmacother; 2023 Feb; 24(3):287-290. PubMed ID: 36461669 [No Abstract] [Full Text] [Related]
28. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression? Malyszko J; Glowinska I; Mysliwiec M Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016 [TBL] [Abstract][Full Text] [Related]
29. Anemia of chronic kidney disease: Treat it, but not too aggressively. Nakhoul G; Simon JF Cleve Clin J Med; 2016 Aug; 83(8):613-24. PubMed ID: 27505883 [TBL] [Abstract][Full Text] [Related]
30. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection]. Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257 [TBL] [Abstract][Full Text] [Related]
32. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit. To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828 [No Abstract] [Full Text] [Related]
33. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Locatelli F; Covic A; Eckardt KU; Wiecek A; Vanholder R; Nephrol Dial Transplant; 2009 Feb; 24(2):348-54. PubMed ID: 19037082 [No Abstract] [Full Text] [Related]
34. Erythropoietin Levels in Elderly Patients with Anemia of Unknown Etiology. Gowanlock Z; Sriram S; Martin A; Xenocostas A; Lazo-Langner A PLoS One; 2016; 11(6):e0157279. PubMed ID: 27310832 [TBL] [Abstract][Full Text] [Related]
35. Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial. Fliser D; Dellanna F; Koch M; Wiggenhauser A; Nephrol Dial Transplant; 2017 Feb; 32(2):279-287. PubMed ID: 28186540 [TBL] [Abstract][Full Text] [Related]
37. The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease. Bazeley J; Wish JB Adv Chronic Kidney Dis; 2019 Jul; 26(4):229-236. PubMed ID: 31477253 [TBL] [Abstract][Full Text] [Related]
38. An ongoing study of anemia correction in chronic kidney disease. Pfeffer MA; N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707 [No Abstract] [Full Text] [Related]
39. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Robles NR Clin Drug Investig; 2016 Jun; 36(6):421-31. PubMed ID: 26894799 [TBL] [Abstract][Full Text] [Related]